Overview

Study of Erlotinib in Combination With Dasatinib

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the highest tolerable dose of Tarceva (erlotinib hydrochloride) that can be given in combination with Sprycel (dasatinib). The safety of this drug combination will also be studied.

Phase:

Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Dasatinib
Erlotinib Hydrochloride